Anthera Announces First Quarter 2013 Financial Report and Conference Call
HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13th. Anthera will host a Corporate Update conference call on May 20th, 2013.
Conference Call Access:
Date: Monday, May 20th, 2013
Time: 5:00 pm Eastern Time
Domestic Dial-in: (877)312-8807
International Dial-in: (253)237-1190
Conference ID: 64577060
To access the 24-hour audio replay, U.S. and Canadian participants may dial (855)859-2056; international participants may dial (404)537-3406. The conference ID for the replay is 64577060. The audio replay will be available until May 27th, 2013.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.
CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., firstname.lastname@example.org or 510-856-5598.
SOURCE Anthera Pharmaceuticals, Inc.
More by this Source
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
Nov 27, 2013, 17:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.